Ibrance Tablets (Palbociclib)

SAVE on IBRANCE™ ordering online from Canada - (USA Prescription Required)

IBRANCE™ (Palbociclib) - Canada Product Information

---

IMPORTANT NOTICE: IBRANCE in Canada is only available in the tablet format. Other jurisdictions may also offer IBRANCE as a capsule.

What is IBRANCE?

IBRANCE is a medication that comes in tablet form, designed to treat a specific type of breast cancer known as hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. It is used in combination with other medications such as an aromatase inhibitor or fulvestrant.

Who can take IBRANCE?

IBRANCE is prescribed for:

• Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor.
• Women whose disease has progressed after prior endocrine therapy, in combination with fulvestrant. Pre- or perimenopausal women should also receive a luteinizing hormone-releasing hormone (LHRH) agonist.

How to take IBRANCE

• Dosage: The typical starting dose is 125 mg taken once daily for 21 days, followed by a 7-day break. This 28-day cycle is repeated as long as the medication is effective and well-tolerated.
• With Food: Always take Ibrance with food.
• Same Time Each Day: Try to take your dose at the same time each day.
• Missed Dose: If you miss a dose or vomit after taking it, do not take an additional dose that day. Take your next dose at the usual time.

Possible Side Effects

Common side effects include:

• Neutropenia (low white blood cell count)
• Infections
• Fatigue
• Nausea
• Anemia (low red blood cell count)
• Hair thinning or loss
• Diarrhea
• Rash
• Decreased appetite

Serious Side Effects:

• Neutropenia with fever or infection: Contact your doctor immediately if you experience fever.
• Severe infections: Monitor for signs of infection and report symptoms to your doctor promptly.

Warnings and Precautions

• Blood Tests: Regular blood tests are needed to monitor blood cell counts.
• Infection Risk: Higher risk of infections; report any signs of infection to your healthcare provider.
• Pregnancy: Not recommended during pregnancy as it can harm the unborn baby.
• Breastfeeding: Not recommended while taking IBRANCE.

Drug Interactions

• Avoid: Strong CYP3A inhibitors (e.g., clarithromycin, itraconazole) and inducers (e.g., rifampin, carbamazepine).
• Grapefruit: Avoid grapefruit and grapefruit juice as they can increase IBRANCE levels in your blood.

Storage

• Temperature: Store at 68°F to 77°F; brief excursions are allowed between 15°C to 30°C 59°F to 86°F.
• Disposal: Dispose of any unused medication according to local regulations.

Supplied

IBRANCE from Canada is supplied in a box containing 3 weekly blister packs of 7 tablets each (21 tablets total). IBRANCE is available in three strengths: 75, 100, and 125 mg tablets.

Always consult with your healthcare provider for more detailed information and guidance tailored to your specific situation.

---

Reference: IBRANCE Canada product monograph

Take IBRANCE 125 mg tablet once daily with food for 21 days, followed by a 7-day break. Continue this 28-day cycle as long as prescribed. Take at the same time each day. If you miss a dose or vomit, skip it and take the next dose at the usual time. Always follow your doctor’s instructions.